<?xml version="1.0" encoding="UTF-8"?>
<p>All of these studies used mononuclear cells from bone marrow concentrate. Usuelli 
 <italic>et al</italic> published a study looking at PRP and SVF. The study concluded that SVF was safe and as efficacious as PRP at 180 days, although this study did not use culture expanded MSCs.
 <xref rid="R10" ref-type="bibr">10</xref> We could only identify one study looking at culture expanded MSCs in AT. IliÄ‡ 
 <italic>et al</italic> reported the use of human placenta-derived allogenic MSCs injected under ultrasound guidance in six patients. They monitored for the primary outcome, which was safety. They concluded it was safe to inject human placenta-derived MSCs into human Achilles tendons, however made no comment on clinical outcome.
 <xref rid="R26" ref-type="bibr">26</xref>
</p>
